195P Health-related quality of life outcomes in SOLTI VALENTINE: A trial of neoadjuvant HER3-DXd +/- letrozole for high-risk hormone receptor positive/HER2-negative early breast cancer
Guillermo Villacampa(Vall d'Hebron Institut de Recerca), Ana Muntañola Prat(Hospital Clínic de Barcelona), M. Munoz(Hospital Clínic de Barcelona), Xavier González(Breast Cancer Research Foundation), J.M. Ferrero-Cafiero(Solti), F.J. Salvador Bofill(Hospital Universitario de Valme), J. Cruz Jurado(Hospital Universitario de Canarias), Pilar Sánchez Henaréjos, M. Borrell Puy(Vall d'Hebron Hospital Universitari), Emily M. Pang(Stanford University), Mikele Praia de Oliveira, K. Amillano Parraga(Hospital Universitari Sant Joan de Reus), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Santiago González(Hospital San Pedro de Alcántara), Elena Gálve(Hospital de Basurto), T. Pascual(Hospital Clínic de Barcelona), M. Paes Dias(Solti), Clara Martínez-Vila(Althaia), M.E. Pérez López(Complexo Hospitalario Universitario A Coruña), Juan Miguel Cejalvo(Universitat de València)
Cited by 1
Related Papers
Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity
|Cell Reports|2014|283
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
|EMBO Molecular Medicine|2018|271
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
|Neuro-Oncology|2022|247